REG - Creo Medical Group - Speedboat™ Inject selected by NICE for assessment

Creo MedicalAnnouncement

01/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230601:nRSA2251Ba&default-theme=true

RNS Number : 2251B  Creo Medical Group PLC  01 June 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Speedboat™ Inject selected by NICE for assessment

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that the National Institute
for Health and Care Excellence ("NICE") has selected Speedboat Inject to be
scoped and routed for guidance in respect of the endoscopic submucosal
dissection ("ESD") of lower gastrointestinal ("GI") lesions.

 

This selection follows a committee review of headline data and initiates a
multi-step process whereby Speedboat's lower GI ESD clinical and economic
evidence, along with other data, is evaluated by NICE and, if appropriate, may
result in a specific NICE output such as Medical Technologies Guidance.

 

NICE selected Speedboat Inject for scoping and routing because it
"anticipate s  the topic will be of importance to patients, carers,
professionals, commissioners and the health of the public to ensure clinical
benefit is realised, inequalities in use addressed, and help them make the
best use of NHS resources".

 

More information on Speedboat's guidance development can be found here
(https://www.nice.org.uk/guidance/awaiting-development/gid-mt602) .

 

Craig Gulliford, CEO of Creo Medical, said: "We are delighted that Speedboat
Inject has reached this stage with NICE and the validation this provides given
the progress we are already making in the UK. We look forward to the outcome
of the final stages of the review process as NICE concludes its work."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cenkos Securities plc                              +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGFKKMKGFZM